Quotient Limited (NASDAQ:QTNT) is reporting second quarter earnings results on Monday 2nd November 2020, before market open.
The consensus estimates from Thomson Reuters are loss of $ 0.33 per share from $ 7.90 million in revenue.
For the full year, analysts predict revenues of $ 34.86 million, while looking forward to loss of $ 1.34 per share.
The Company Outlook
Full Year 2021 topline are forecasted in a range of$ 32.00 million ~ $ 34.00 million
Click Here For More Historical Outlooks Of Quotient Limited
Previous Quarter Performance
Quotient Limited reported loss for the first quarter of $ 0.32 per share, from the revenue of $ 8.92 million. Street analysts expected Quotient Limited to report loss of $ 0.33 per share on revenue of $ 8.67 million for the first quarter. The bottom line results beat street analysts by $ 0.01 or 3.03 percent, at the same time, top line results outshined analysts by $ 0.25 million or 2.88 percent.
Stock Performance
On Friday, shares of Quotient Limited has traded high as $ 4.72 and has cracked $ 4.45 on the downward trend, reaching $ 4.72 with volume of 684.90 thousand shares.
According to the previous trading day, closing price of $ 4.72, representing a 89.58 % increase from the 52 week low of $ 2.40 and a 56.17 % decrease over the 52 week high of $ 10.38.
The company has a market capital of $ 476.25 million and is part of the Healthcare sector and Diagnostics & Research industry.
Conference Call
Quotient Limited will be hosting a conference call at 8:00 AM eastern time on 2nd November 2020, to discuss its 2Q21 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website quotientbd.com
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood-group antigens; reagent red blood cells, which enable the identification of blood-group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping.
